Connect with us

Hi, what are you looking for?

Jewish Business News

StartUps

Leviticus Cardio Completes a Successful Animal Trial for its Wireless Energy System for VADs

 –

Leviticus Cardio 2

By Ilan Shavit /

Leviticus Cardio, a portfolio company of the Mofet Venture Accelerator , owned by the Trendlines Group, recently performed a successful animal surgical trial using its wireless coplanar energy transfer system (CET) for ventricular assist devices (VAD). The surgery was performed at Assaf Harofeh Hospital In Israel, and produced a 75% full system efficiency rate as compared with 78% efficiency in vitro.

 

The animal trials were done using the Leviticus CET system and Jarvik Heart VAD. The CET system performed the energy transfer to the animal body and controlled the VAD pump operation.

 

In vitro lab tests were conducted using several commercial VAD systems of Thoratec, Heartware, Jarvik Heart and Cleveland Heart. In all these tests, the Leviticus CET system was used to transfer the energy and to control the VAD pumping operation using the Leviticus advanced controller.

 

Leviticus Cardio was selected to present the results of these in vitro and in vivo tests as part of the scientific program in ISHLT 2013 convention held at Montreal.

 

VADs are used to extend the lives of thousands of patients suffering from chronic heart failure or waiting for a heart transplant. Today, VAD patients are connected with wires to an external power supply – risking dangerous infections, repeated hospitalizations and severely limiting mobility. Leviticus Cardio’s wireless CET system powers the VAD without wires, thereby avoiding the complications associated with today’s technologies. In addition, the Leviticus Cardio’s system can easily be removed for limited periods of time to give patients complete freedom of movement without any external device attached.

 

Michael Zilbershlag, Leviticus co-founder and CEO stated, “This successful trial is a significant milestone in validating our technology and advancing towards commercialization. We are especially fortunate to be working with Prof. Stephan Schueler, M.D., a leading cardiothoracic surgeon in Europe and with the support from VAD manufacturer Jarvik Heart for the procedures.”

 

Prof. Schueler remarked: “This new device allows us to apply the VAD technology to a wider group of patients outside of the transplant patients’ group. For them, to have all the advantages of a wireless technology will have a huge impact on their morbidity and even mortality, and quite obviously on their quality of life.”

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Newsletter

Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

empty

The contract signed between the Israeli government and Pfizer shows clearly and unequivocally that this is a clinical study on humans - The agreement...

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

Business

Now Platika joins and elite club of $10 billion plus Israeli firms.

Advertisement
cialis cialis satış